UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
   
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30,December 31, 2010
OR
   
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 0-11250
DIONEX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
   
Delaware 94-2647429
   
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
   
1228 Titan Way, Sunnyvale, California 94085
   
(Address of principal executive offices) (Zip Code)
(408) 737-0700
(Registrant’s Telephone Number, including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YESþ NOo
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YESþ NOo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerþ Accelerated filero Non-accelerated filero Smaller reporting companyo
  (Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YESo NOþ
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of November 4, 2010:February 3, 2011:
   
CLASS NUMBER OF SHARES
Common Stock 17,421,07117,478,308
 
 

 


 

DIONEX CORPORATION
INDEX
     
  Page (s)
  3 
  3 
  3 
  4 
  56 
  67 
  1618 
  2023 
  2124 
  22
24 
  2224 
  2529 
  27
ITEM 6. Exhibits30 
  2831 
 EX-31.1
 EX-31.2
 EX-32.1
 EX-32.2
 EX-101 INSTANCE DOCUMENT
 EX-101 SCHEMA DOCUMENT
 EX-101 CALCULATION LINKBASE DOCUMENT
 EX-101 LABELS LINKBASE DOCUMENT
 EX-101 PRESENTATION LINKBASE DOCUMENT

2


Part I. Financial Information
Item 1. Financial Statements
DIONEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
                
 September 30, June 30,  December 31, June 30, 
 2010 2010  2010 2010 
ASSETS  
Current assets:  
Cash and cash equivalents $76,852 $69,830  $92,523 $69,830 
Short-term investments 176 448  2 448 
Accounts receivable (net of allowance for doubtful accounts of $524 and $543 as of September 30, 2010 and June 30, 2010, respectively) 86,752 86,780 
Accounts receivable (net of allowance for doubtful accounts of $526 at December 31, 2010 and $543 at June 30, 2010) 87,721 86,780 
Inventories 41,562 37,458  43,580 37,458 
Deferred taxes 14,001 14,036  13,151 14,036 
Prepaid expenses and other current assets 21,576 18,991  25,058 18,991 
          
Total current assets 240,919 227,543  262,035 227,543 
Property, plant and equipment, net 80,623 76,062  79,984 76,062 
Goodwill 35,913 35,013  35,779 35,013 
Intangible assets, net 17,654 13,859  16,859 13,859 
Other assets 10,213 9,511  9,958 9,511 
          
 $385,322 $361,988  $404,615 $361,988 
          
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
Borrowings under line of credit $17,371 $3,149  $52 $3,149 
Accounts payable 14,633 17,303  16,987 17,303 
Accrued liabilities 32,993 33,980  38,497 33,980 
Deferred revenue 25,985 25,203  23,352 25,203 
Income taxes payable 3,605 5,247  4,174 5,247 
Accrued product warranty 2,617 2,532  2,620 2,532 
          
Total current liabilities 97,204 87,414  85,682 87,414 
Deferred and other income taxes payable 19,160 16,427  18,551 16,427 
Other long-term liabilities 7,616 7,272  9,227 7,272 
Commitments and other contingencies (Note 12)  
Stockholders’ equity:  
Dionex Corporation stockholders’ equity  
Preferred stock (par value $.001 per share; 1,000,000 shares authorized; none outstanding)      
Common stock (par value $.001 per share; 80,000,000 shares authorized; issued and outstanding: 
17,301,892 shares as of September 30, 2010 and 17,437,276 shares as of June 30, 2010) and capital in excess of par value 210,507 207,855 
Common stock (par value $.001 per share; 80,000,000 shares authorized; issued and outstanding: 17,458,231 shares at December 31, 2010 and 17,437,276 shares at June 30, 2010) 222,796 207,855 
Retained earnings 33,435 34,195  50,701 34,195 
Accumulated other comprehensive income 15,128 6,733  15,581 6,733 
          
Total Dionex Corporation stockholders’ equity 259,070 248,783  289,078 248,783 
Noncontrolling interests 2,272 2,092  2,077 2,092 
          
Total stockholders’ equity 261,342 250,875  291,155 250,875 
          
 $385,322 $361,988  $404,615 $361,988 
          
See notes to condensed consolidated financial statements.

3


DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
(Unaudited)
                
 Three Months Ended  Three Months Ended 
 September 30,  December 31, 
 2010 2009  2010 2009 
Net sales $102,874 $90,664  $124,111 $109,164 
Cost of sales 36,472 31,041  43,322 36,975 
          
Gross profit 66,402 59,623  80,789 72,189 
          
Operating expenses:  
Selling, general and administrative 40,266 35,983  43,920 40,503 
Research and product development 8,013 7,172  9,370 7,654 
          
Total operating expenses 48,279 43,155  53,290 48,157 
          
Operating income 18,123 16,468  27,499 24,032 
Interest income 60 83  61 32 
Interest expense  (33)  (36)  (38)  (36)
Other income (expense), net  (1,038) 40 
Other expense, net  (516)  (494)
          
Income before taxes 17,112 16,555  27,006 23,534 
Taxes on income 5,790 5,969  8,148 6,614 
          
Net income 11,322 10,586  18,858 16,920 
Less: Net income attributable to noncontrolling interests 361 250  383 338 
          
Net income attributable to Dionex Corporation $10,961 $10,336  $18,475 $16,582 
          
 
Basic earnings per share attributable to Dionex Corporation $0.63 $0.58  $1.06 $0.94 
          
Diluted earnings per share attributable to Dionex Corporation $0.62 $0.57  $1.04 $0.92 
          
Shares used in computing per share amounts:  
Basic 17,388 17,712  17,394 17,654 
Diluted 17,698 18,050  17,802 18,025 
See notes to condensed consolidated financial statements.

4


DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
(Unaudited)
         
  Six Months Ended 
  December 31, 
  2010  2009 
Net sales $226,985  $199,828 
Cost of sales  79,794   68,015 
       
Gross profit  147,191   131,813 
       
Operating expenses:        
Selling, general and administrative  84,186   76,487 
Research and product development  17,383   14,825 
       
Total operating expenses  101,569   91,312 
       
Operating income  45,622   40,501 
Interest income  121   115 
Interest expense  (71)  (72)
Other expense, net  (1,554)  (454)
       
Income before taxes  44,118   40,090 
Taxes on income  13,938   12,583 
       
Net income  30,180   27,507 
Less: Net income attributable to noncontrolling interests  744   588 
       
Net income attributable to Dionex Corporation $29,436  $26,919 
       
         
Basic earnings per share $1.69  $1.52 
       
Diluted earnings per share $1.66  $1.49 
       
Shares used in computing per share amounts:        
Basic  17,391   17,678 
Diluted  17,750   18,032 
See notes to condensed consolidated financial statements.

5


DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
                
 Three Months Ended  Six Months Ended 
 September 30,  December 31, 
 2010 2009  2010 2009 
Cash flows from operating activities:  
Net income $11,322 $10,586  $30,180 $27,507 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization 3,380 2,478  7,370 5,787 
Stock-based compensation 1,972 1,578  4,158 3,275 
Bad debt recoveries  (114)  (155)
Provision for bad debts  (113) 16 
Loss on disposal of fixed assets 341 29  485 207 
Tax benefit related to stock transactions  (337)  (165)  (2,335)  (992)
Deferred income taxes 89  (5)  (298) 5 
Changes in assets and liabilities, net of acquired assets and assumed liabilities:  
Accounts receivable 4,500 2,435  3,894  (14,198)
Inventories  (734)  (1,656)  (2,407)  (3,651)
Prepaid expenses and other current assets  (543) 753 
Prepaid expenses and other assets  (970) 55 
Prepaid income taxes  (1,756) 2,521   (4,230) 2,616 
Accounts payable  (2,854) 783   (521) 1,463 
Accrued liabilities  (3,186)  (1,685) 1,823 5,388 
Deferred revenue  (317) 1,101   (2,017) 5,735 
Income taxes payable  (1,214) 4,457  2,544 4,742 
Accrued product warranty  (59)  (173)  (58)  (361)
          
Net cash provided by operating activities 10,490 22,882  37,505 37,594 
          
Cash flows from investing activities:  
Proceeds from sale of marketable securities 288 232  452 233 
Purchase of property, plant and equipment  (5,178)  (2,751)  (7,757)  (6,880)
Purchase of intangible assets  (4,512)  (21,100)
Purchase of business  (4,512)  (21,100)
          
Net cash used for investing activities  (9,402)  (23,619)  (11,817)  (27,747)
          
Cash flows from financing activities:  
Net borrowings under line-of-credit 14,222 15,075   (3,092) 13,553 
Proceeds from issuance of common stock 2,577 3,261  10,867 9,514 
Tax benefit related to stock transactions 337 165  2,335 992 
Repurchase of common stock  (13,952)  (11,175)  (15,349)  (22,024)
Dividends paid to noncontrolling interests   (104)   (453)
          
Net cash provided by financing activities 3,184 7,222 
Net cash provided by (used for) financing activities  (5,239) 1,582 
          
Effect of exchange rate changes on cash 2,750 2,065  2,244 273 
          
Net increase in cash and cash equivalents 7,022 8,550 
Net increase (decrease) in cash and cash equivalents 22,693 11,702 
Cash and cash equivalents, beginning of period 69,830 69,684  69,830 69,684 
          
Cash and cash equivalents, end of period $76,852 $78,234  $92,523 $81,386 
          
Supplemental disclosures of cash flow information:  
Income taxes paid $8,907 $1,803  $15,789 $8,179 
Interest expense paid 28 28  60 58 
Supplemental schedule of non-cash investing and financing activities:  
Accrued purchases of property, plant and equipment 106 588  184 665 
See notes to condensed consolidated financial statements

56


DIONEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1: Summary of Significant Accounting Policies
Organization and Basis of Presentation
The condensed consolidated financial statements included herein have been prepared by Dionex Corporation, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2010. Unless the context otherwise requires, the terms “Dionex,” “we,” “our” and “us” and words of similar import as used in these notes to condensed consolidated financial statements include Dionex Corporation and its consolidated subsidiaries.
The unaudited condensed consolidated financial statements included herein reflect all adjustments (which include only normal, recurring adjustments) that are, in the opinion of management, necessary to state fairly the results for the periods presented. The results for such periods are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2011.
On December 12, 2010, Dionex, Thermo Fisher Scientific, Inc., a Delaware corporation (“Thermo Fisher”), and Weston D Merger Co., a Delaware corporation and a wholly owned subsidiary of Thermo Fisher (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Merger Sub will, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, merge with and into Dionex and Dionex will survive the merger and continue as a wholly owned subsidiary of Thermo Fisher (the “Merger”). Pursuant to the terms of the Merger Agreement and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each share of common stock of Dionex issued and outstanding immediately prior to the Effective Time will be converted into the right to receive $118.50 in cash, without interest.
The Merger Agreement includes customary representations, warranties and covenants of Dionex and Thermo Fisher. Dionex has agreed to operate its business and the business of its subsidiaries in the ordinary course of business consistent with past practices until the Effective Time. Dionex has also agreed not to solicit, initiate, knowingly encourage or knowingly facilitate alternative acquisition proposals and will not knowingly permit its representatives to solicit or encourage any alternative acquisition proposal, in each case, subject to certain exceptions set forth in the Merger Agreement. The Merger Agreement contains certain termination rights, including, subject to the terms of the agreement, if the Dionex Board of Directors determines to accept a “Superior Proposal” as defined in the Merger Agreement, and also provides that under certain circumstances, upon termination, Dionex may be required to pay Thermo Fisher a termination fee of $65 million. The closing of the merger is currently expected to take place early in our fiscal fourth quarter due to pending regulatory approvals.
New Accounting Standards Adopted
Transfers of Financial Assets
In June 2009, the Financial Accounting Standards Board (“FASB”) issued new standards for the accounting for transfers of financial assets. These new standards amend the criteria for a transfer of a financial assetsasset to be accounted for as a sale, establish more stringent conditions for reporting a transfer of a portion of a financial asset as a sale, change the initial measurement of a transferor’s interest in transferred financial assets, eliminate the qualifying special-purpose entity concept and require enhanced disclosures. Dionex adopted these standards in the first quarter of fiscal 2011 and they did not have a material impact on our consolidated financial statements but did expand our disclosures about transfers of financial assets. Refer to Note 7 for additional information.
Financial Instruments
In January 2010, the FASB issued a new accounting standard to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance

7


requires a roll forward of activities on purchases, sales, issuance, and settlements of the assets and liabilities measured using significant unobservable inputs (Level 3 fair value measurements). The guidance became effective for us with the reporting period beginning January 1, 2010, except for the disclosure on the roll forward activities for Level 3 fair value measurements, which iswas effective for us in the first quarter of fiscal 2011. Other than requiring additional disclosures, adoption of this new standard did not have a material impact on our consolidated financial statements or any additional disclosures as Dionex did not have any financial instruments transfers between Level 1 and 2 during the threesix months ended September 30,December 31, 2010.
Revenue Recognition
Net sales are derived primarily from sales of products, software licenses, and services (including installation, training, other consulting services, and extended maintenance contracts on our products). The following revenue recognition policies define the manner in which Dionex accounts for sales transactions.
Dionex recognizes revenue when persuasive evidence of an arrangement exists, the product has been delivered or service has been performed, the sales price is fixed or determinable, and collection is reasonably assured. Delivery of the product is generally considered to have occurred when shipped. Shipping charges billed to customers are included in net sales, and the related costs are included in cost of sales. Sales from products are typically not subject to rights of return and, historically, actual sales returns have not been significant. Dionex sells products through its direct sales force and through distributors and resellers. Sales through distributors and resellers are recognized as revenue upon sale to the distributor or reseller as these sales are considered to be final and no right of return or price protection exists.

6


Customer acceptance is generally limited to performance under our published product specifications. When additional customer acceptance conditions apply, all revenue related to the sale is deferred until acceptance is obtained.
In October 2009, the FASB issued a new accounting standard for multiple deliverable revenue arrangements. The new standard changes the requirements for establishing separate units of accounting in a multiple element arrangement and requires the allocation of arrangement consideration to each deliverable to be based on the relative selling price. The FASB also issued a new accounting standard for certain revenue arrangements that include software elements. This new standard excludes software that is contained on a tangible product from the scope of software revenue guidance if the software is essential to the tangible product’s functionality. Dionex prospectively adopted both these standards in the first quarter of fiscal 2011 for new and materially modified arrangements originating after July 1, 2010. The impact of adopting these standards was not material to net sales on our condensed consolidated financial statements for the three-monthssix months ended September 30,December 31, 2010. The new accounting standard for revenue recognition if applied in the same manner to the year ended June 30, 2010 would not have had a material impact on net sales or to our consolidated financial statements for that fiscal year. Dionex anticipates the effect of the adoption of these standards in future periods will primarily depend upon the nature and volume of new or materially modified arrangements.
Under these new standards, when a sales arrangement contains multiple elements, such as products, software licenses and/or services, Dionex allocates revenue to each element based on a selling price hierarchy. Using the selling price hierarchy, Dionex determines selling price of each deliverable using vendor specific objective evidence (“VSOE”), if it exists, and otherwise third-party evidence (“TPE”). If neither VSOE nor TPE of selling price exists, Dionex uses estimated selling price (“ESP”). Dionex generally expects that it will not be able to establish TPE due to the nature of the markets in which we compete, and, as such, Dionex typically will determine selling price using VSOE or if not available, ESP.
Dionex’s basis for establishing VSOE of a deliverable’s selling price consists of standalone sales transactions when the same or similar product or service is sold separately. However, when services are never sold separately, such as product installation services, VSOE is based on the product’s estimated installation hours based on historical experience multiplied by the standard service billing rate. In determining VSOE, Dionex requires that a substantial majority of the selling priceprices for a product or service fall within a reasonably narrow price or hour range, as defined by Dionex. Dionex also considers the geographies in which the products or services are sold, major product and service groups, and other environmental variables in determining VSOE. Absent the existence of VSOE and TPE, our determination of a deliverable’s ESP involves evaluating several factors based on the specific facts and circumstances of these arrangements, which include pricing strategy and policies driven by geographies, market conditions, competitive landscape, correlation between proportionate selling price and list price established by management having the relevant authority, and other environmental variables in which the deliverable is sold.
For multiple element arrangements which include extended maintenance contracts, Dionex allocates and defers the amount of consideration equal to the separately stated price and recognizes revenue on a straight-line basis over the contract period.
For multiple element arrangements which contain software deliverables and non-software deliverables (i.e. instruments) where the instruments’ essential functionality is not dependent on both deliverables functioning together, revenue is allocated to the software

8


deliverables as a group using the relative selling prices of each deliverable in the arrangement based on the selling price hierarchy. The consideration allocated to the software deliverable group is then allocated to each software deliverable within that group in accordance with software revenue recognition guidance.
For perpetual software licenses, Dionex recognizes revenue at the inception of the license term assuming all revenue recognition criteria have been met. Dionex uses the residual method to allocate revenue to software licenses at the inception of the license term when VSOE of fair value for the undelivered elements exists, such as software installations, and all other revenue recognition criteria have been satisfied. If Dionex cannot objectively determine the VSOE of fair value of any undelivered elements included in these multiple-element arrangements, revenue is deferred until all elements are delivered, or until VSOE of fair value can be objectively determined for the remaining undelivered elements.
Note 2: Earnings Per Share
Basic earnings per share attributable to Dionex Corporation are determined by dividing net income attributable to Dionex Corporation by the weighted average number of common shares outstanding during the period. Diluted earnings per share attributable to Dionex Corporation are determined by dividing net income attributable to Dionex Corporation by the weighted average number of common shares used in the basic earnings per share calculation, plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding under the treasury stock method.

7


The following table is a reconciliation of the numerators and denominators used in computing basic and diluted earnings per share attributable to Dionex Corporation (in thousands, except per share data):
         
  Three Months Ended 
  September 30, 
  2010  2009 
Numerator:        
Net income attributable to Dionex Corporation $10,961  $10,336 
Denominator:        
Weighted average shares used to compute earnings per share attribution to Dionex Corporation — basic  17,388   17,712 
Effect of dilutive stock options  310   338 
       
Weighted average shares used to compute earnings per share attribution to Dionex Corporation— diluted  17,698   18,050 
       
Basic earnings per share attributable to Dionex Corporation $0.63  $0.58 
       
Diluted earnings per share attributable to Dionex Corporation $0.62  $0.57 
       
         
Antidilutive common equivalent shares related to stock awards are excluded from the calculation of diluted earnings per share attribution to Dionex Corporation  594   622 
                 
  Three Months Ended  Six Months Ended 
  December 31,  December 31, 
  2010  2009  2010  2009 
Numerator:                
Net income $18,475  $16,582  $29,436  $26,919 
Denominator:                
Weighted average shares used to compute net income per common share — basic  17,394   17,654   17,391   17,678 
Effect of dilutive stock options  408   371   359   354 
             
Weighted average shares used to compute net income per common share — diluted  17,802   18,025   17,750   18,032 
             
Basic earnings per share $1.06  $0.94  $1.69  $1.52 
             
Diluted earnings per share $1.04  $0.92  $1.66  $1.49 
             
Stock options to purchase 761,273 shares and 492,970 shares were excluded from the computation of diluted earnings per share in the three and six months ended December 31, 2009, respectively, because the exercise price of the stock options exceeded the average market price of the Company’s common stock and, as a result, would have had an anti-dilutive effect. There were no anti-dilutive shares for the three and six months ended December 31, 2010.
Note 3: Fair Value Measurements
In accordance with the accounting standards for fair value measurements and disclosures, assets and liabilities are measured at fair value on a recurring basis as of the end of each reporting period. Dionex applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
  Level 1 inputinputs utilize observable data such as quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
 
  Level 2 inputs utilize data points other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.
 
  Level 3 inputs utilize unobservable data points for the asset ofor liability in which there is little or no market data, which require the reporting entity to develop its own assumptions.

9


The following table summarizes our assets and liabilities measured at fair value on a recurring basis as of September 30,December 31, 2010:
                                
(in thousands) Total Level 1 Level 2 Level 3  Total Level 1 Level 2 Level 3 
Assets:  
Money market (1) $81 $81 $ $  $8,847 $8,847 $ $ 
Equity indexed derivatives (2) 176  176   2  2  
                  
Total $257 $81 $176 $  $8,849 $8,847 $2 $ 
                  
Liabilities:  
Foreign currency contracts (3) $5,709 $ $5,709 $  $5,003 $ $5,003 $ 
                  
 
(1) Included in “cash and cash equivalents” in theour condensed consolidated balance sheetssheets.
 
(2) Included in “short-term investments” in theour condensed consolidated balance sheets. The gross unrealized loss is not material.
 
(3) Included in “other long-term liabilities” or “other accrued liabilities” in theour condensed consolidated balance sheetssheets.
Note 4: Derivative Securities
All derivatives, whether designated in hedging relationships or not, are required to be recorded on theour consolidated balance sheets at fair value as either assets or liabilities. If the derivative is designated as a fair-value hedge, the changes in the fair value of the derivative and of the hedged item attributable to the hedged risk are recognized in earnings. If the derivative is designated as a cash flow hedge or net investment hedge, the effective portions of changes in the fair value of the derivative are recorded in other comprehensive income and are recognized in earnings when the hedged item affects earnings; ineffective portions of changes in fair value are recognized in earnings.

8


Dionex operates on a global basis and is exposed to foreign currency exchange rate fluctuations in the normal course of its business. As part of its risk management strategy, Dionex uses derivative instruments to manage exposures to foreign currency. The objective is to offset gains and losses resulting from these exposures with losses and gains on the derivative contracts used to hedge them, thereby reducing volatility of earnings or protecting fair value of assets and liabilities. Dionex does not have any leveraged derivatives nor use derivative contracts for speculative purposes.
Net Investment Hedge
Dionex uses a $10 million cross-currency swap arrangement for Japanese yen that expires in March 2012 to hedge the exchange rate exposure of our net investment in our Japanese subsidiary. Dionex considers the impact of its counterparty’s credit risk on the fair value of the contract as well as the ability ofto each party to execute under the contract. Dionex assessed and documented hedge effectiveness of the contract and designated it as a net investment hedge at the inception date, January 1, 2008. We reassess hedgeedge effectiveness on a quarterly basis. The gain or loss related to the effective portion of the hedge is reported in accumulated other comprehensive income as part of the foreign currency translation adjustment, and the gain or loss related to the ineffective portion, if any, is reported in other income (expense).,net.
Other Derivatives
Other derivatives not designated as hedging instruments consist primarily of foreign exchange forward contracts with high quality financial institutions to manage our exposure to the impact of fluctuations in foreign currency exchange rates on our intercompany receivables balances. Principal hedged currencies include the Euro, Japanese yen, Australian dollar, Canadian dollar, British pound sterling, and Canadian dollar.Swiss Francs. The periods of these forward contracts is approximately 30 days and have varying notional amounts that are intended to be consistent with changes in the underlying exposures and require Dionex to exchange foreign currencies for U.S. dollars at maturity. Gains (losses) on these contracts are reported as other income (expense) in the current period earnings.

10


Total gross notional amounts for outstanding derivatives were as follows:
                
 September 30, June 30,  December 31, June 30, 
(in thousands) 2010 2010  2010 2010 
Derivatives not designated as hedging instruments  
Currency forwards:  
Euro $23,793 $17,659  $8,763 $17,659 
Japanese yen 6,683 4,282  6,378 4,282 
Australian dollar 1,052 791  1,217 791 
Canadian dollar 1,205 853  1,197 853 
British pound sterling 3,755  
Swiss Francs 564  
Derivatives designated as hedging instruments  
Currency swaps 10,000 10,000  10,000 10,000 
          
Total $42,733 $33,585  $31,874 $33,585 
          
The following table shows derivative instruments measured at gross fair value and balance sheet location on the condensed consolidated balance sheet:
                                
 September 30, 2010 June 30, 2010 December 31, 2010June 30, 2010
 Accrued Other Long- Accrued Other Long- Accrued Other Long- Accrued Other Long-
(In thousands) Liabilities Term Liabilities Liabilities Term Liabilities Liabilities Term Liabilities Liabilities Term Liabilities
Derivatives designated as hedging instruments  
Currency swaps $ $4,211 $ $3,390  $ $4,576 $ $3,390 
Derivatives not designated as hedging instruments  
Currency forwards $1,498 $ $290 $  $427 $ $290 $ 

9


The following table shows the effect of derivative instruments designated as hedging instruments and not designated as hedging instruments in the condensed consolidated statements of operations in the three and six months ended September 30:December 31, 2010 and 2009:
                
 Three Months Six Months 
         Ended December 31,Ended December 31, 
(In thousands) 2010 2009 2010 2009 2010 2009 
Derivatives designated as hedging instruments  
Net investment hedges  
Unrealized gain/ (loss) recognized in other comprehensive income on derivatives $(821) $(901) $(365) $359 $(1,186) $(542)
Realized gain/ (loss) reclassified from other comprehensive income into income $ $  $ $ $ $ 
 
Derivatives not designated as hedging instruments  
Currency forwards  
Realized gain / (loss) included other income/(expense), net $(2,161) $(661) $(848) $34 $(3,009) $(627)
Note 5: Balance Sheet Details
The following tables provide details of selected balance sheet items:
                
 September 30, June 30,  December 31, June 30, 
(in thousands) 2010 2010  2010 2010 
Inventories:
  
Finished goods $25,733 $23,788  $26,756 $23,788 
Work in process 1,542 1,781  1,799 1,781 
Raw materials 14,287 11,889  15,025 11,889 
          
 $41,562 $37,458  $43,580 $37,458 
          
                
 September 30, June 30,  December 31, June 30, 
 2009 2010  2010 2010 
Property, Plant and Equipment, net:
  
Land $27,859 $25,098  $27,931 $25,098 
Buildings and improvements 50,407 48,396  50,825 48,396 
Machinery, equipment and tooling 53,082 50,411  54,090 50,411 
Furniture and fixtures 13,219 12,194  13,362 12,194 
Construction-in-progress 25 13  13 13 
          
 144,592 136,112  146,221 136,112 
Accumulated depreciation and amortization  (63,969)  (60,050)  (66,237)  (60,050)
          
Property, plant and equipment, net $80,623 $76,062  $79,984 $76,062 
          

11


Depreciation expense was $2.6 million and $2.2$2.4 million in three months ended September 30,December 31, 2010 and 2009, respectively and $5.2 million and $4.6 million in six months ended December 31, 2010 and 2009, respectively.
Note 6: Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill were as follows for the threesix months ended September 30,December 31, 2010:
        
(in thousands)  
Balance as of June 30, 2010 $35,013  $35,013 
Additions 12  11 
Foreign currency translation impact 888  755 
      
Balance as of September 30, 2010 $35,913 
Balance as of December 31, 2010 $35,779 
      
Intangible assets (net of accumulated amortization) were as follows:
                                                
 As of September 30, 2010 As of June 30, 2010  As of December 31, 2010 As of June 30, 2010 
 Carrying Accumulated Carrying Accumulated    Carrying Accumulated Carrying Accumulated   
(in thousands) Amount Amortization Net Amount Amortization Net  Amount Amortization Net Amount Amortization Net 
Patents and trademarks $8,788 $(2,730) $6,058 $8,788 $(2,580) $6,208  $8,788 $(2,881) $5,907 $8,788 $(2,580) $6,208 
Developed technology 9,840  (1,332) 8,508 14,893  (10,456) 4,437  9,800  (1,720) 8,080 14,893  (10,456) 4,437 
Customer relationships 5,322  (2,234) 3,088 5,119  (1,905) 3,214  5,356  (2,484) 2,872 5,119  (1,905) 3,214 
                          
Total $23,950 $(6,296) $17,654 $28,800 $(14,941) $13,859  $23,944 $(7,085) $16,859 $28,800 $(14,941) $13,859 
                          
As a result of certain acquisitions, Dionex recorded trade names (intangible assets) totaling $2.8 million, which isare not subject to amortization and isare included in Patentpatents and trademarks.

10


Amortization expense related to all finite intangible assets was $0.8 million and $0.3$0.6 million in the three months ended September 30,December 31, 2010 and 2009, respectively and $1.6 million and $0.9 million in the six months ended December 31, 2010 and 2009, respectively.
Estimated future amortization expense related to finite lived intangible assets as of September 30,December 31, 2010 is as follows:
        
 Remaining Remaining 
 Amortization Amortization 
(in thousands) Expense Expense 
Remainder of Fiscal 2011 $2,394  $1,598 
Fiscal 2012 2,878  2,878 
Fiscal 2013 2,234  2,234 
Fiscal 2014 1,775  1,775 
Fiscal 2015 1,374  1,371 
After Fiscal 2015 4,179  4,173 
      
Total $14,834  $14,029 
      
Note 7: Financing Arrangements
Dionex has unsecured credit agreements with domestic and international financial institutions. The agreements provide for revolving unsecured lines of credit that we utilize primarily for our general corporate purposes, including stock repurchases and working capital needs. As of September 30,December 31, 2010, we had a total of $29.2$28.9 million in available lines of credit, maturing on December 31, 20102011 at an annual interest rate of approximately 1.9%, under which we had borrowed $17.4 million..
One of our foreign subsidiaries transfers certain customer receivables to financial institutions at a discount up to approximately 2% (“discounted notes”) and accounts for these transfers as sales. The purpose of these transfers is to facilitate the funding of outstanding customer receivables by the Company. In the unlikely event that there is failure by the customers to repay the financial institutions for the discounted notes sold by Dionex, Dionex would be required to repurchase the discounted notes back, up to the specified amount outstanding. Under no other circumstance is Dionex obligated or do we have a right to repurchase these discounted notes. Dionex has determined that the fair value of these contingent liabilities under these arrangements are not material as of September 30,December 31, 2010 based

12


on past experience of transferring discounted notes, which considers customers’ credit quality, historical loss experience, and whether the repurchase (if required in the event of a default) is probable and reasonably estimable. The length of time that these discounted notes are outstanding is approximately 90 days and during the three-monthssix-months ended September 30,December 31, 2010, Dionex recorded no losses as a result of customers’ failures to repay the financial institutions. Total discounted notes transferred to the financial institutions during the threesix months ended September 30,December 31, 2010 was $1.2$6.1 million and outstanding discounted notes sold as of September 30,December 31, 2010 was approximately $1.2$4.9 million.
Note 8: Warranty
Dionex accrues estimated product warranty costs at the time of sale, which are included in cost of sales in the consolidated statements of operations. While Dionex engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component supplies, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. The amount of the accrued warranty liability is based on historical information, such as past experience, product failure rates, number of units repaired and estimated costs of material and labor. The liability is reviewed for reasonableness at least quarterly.
The changes in the warranty provision were as follows during the threesix months ended September 30:December 31:
                
(in thousands) 2010 2009  2010 2009 
Balance, beginning $2,532 $3,028 
Balance as of June 30 $2,532 $3,028 
Additions 1,266 881  2,663 1,595 
Effects of foreign currencies exchange 144 98  152 61 
Settlements  (1,325)  (1,020)  (2,727)  (1,920)
          
Balance, end $2,617 $2,987 
Balance as of December 31 $2,620 $2,764 
          
Note 9: Stock-Based Compensation
Dionex’s Board of Directors authorized the 2004 Equity Incentive Plan (the “2004 Plan”). Shares reserved for future issuance under the 2004 Plan may be used for grants of stock options (“options”), restricted stock units (“RSU”RSUs”), and other types of awards.
Dionex also sponsors the Employee Stock Purchase Plan (the “ESPP”) in which eligible employees may contribute up to 10% of their base compensation to purchase shares of common stock at a price equal to 85% of the lower of the market value of the stock at the beginning or end of each six-month offer period, subject to certain annual limitations. Employees purchased 18,831 shares during the

11


three months ended September 30, 2011 for approximately $1.1 million under the ESPP.
Performance Stock Units
Starting in the first quarter of fiscal 2011, Dionex issued performance stock units (“PSUs”) to certain executive officers. The number of shares ultimately received will depend on specified performance targets related to revenue and diluted earnings per share growth rates over a two-year performance period (the “performance period”). Fifty percent of the shares awarded vest at the end of the performance period and remaining shares vest twenty-five percent on each of the following two anniversaries after the performance period assuming continued service by the employee. Delivery of the shares occurs upon achievement of the targets and as of the vesting date.
Dionex estimates the fair value of the PSUs based on the number of PSUs that are expected to be earned multiplied by the market price of Dionex’s common stock on the date of grant. As the performance targets are considered performance conditions, the expense for these awards, net of estimated forfeitures, is recorded over the four year vesting period based on a graded accelerated vesting method.

13


The following table summarizes PSU activity under the 2004 Plan during the threesix months ended September 30,December 31, 2010:
                
 Wtd. Avg. Wtd. Avg.
 Grant-Date   Grant-Date
 Shares Fair Value Shares Fair Value
PSUs outstanding as of June 30, 2010      
Granted 11,688 $76.30  11,688 $76.30 
Vested      
Changes in PSUs due to performance conditions      
Forfeited      
      
PSUs outstanding as of September 30, 2010 11,688 $76.30 
PSUs outstanding as of December 30, 2010 11,688 $76.30 
      
As of September 30,December 31, 2010, there was $0.8were $0.7 million in unrecognized compensation costs related to PSUPSUs granted under the 2004 Plan. These costs are expected to be recognized over a weighted average period of 3.83.5 years.
Restricted Stock Units
The following table summarizes RSU activity under the 2004 Plan during the threesix months ended September 30,December 31, 2010:
                
 Wtd. Avg. Wtd. Avg.
 Grant-Date Grant-Date
 Shares Fair Value Shares Fair Value
RSUs outstanding as of June 30, 2010(1) 87,776 $64.21  87,776 $64.21 
Granted 34,241 76.30  43,970 79.85 
Others (1) 6,800 59.26 
Released     (4,719) 90.46 
Canceled  (2,325) 67.18   (3,142) 67.64 
      
RSUs outstanding as of September 30, 2010 119,692 $67.61 
    
RSUs outstanding as of December 31, 2010 130,685 $68.18 
   
(1)Total RSUs outstanding as of June 30, 2010 previously reported excluded 6,800 RSUs to certain executives of the company. Such amounts have been added to the table above under “Others”.
As of September 30,December 31, 2010, there was $5.9were $6.2 million in unrecognized compensation costs related to RSURSUs granted under the 2004 Plan. These costs are expected to be recognized over a weighted average period of 3.6 years.
Stock Options
The following table summarizes option activity under the 2004 Plan during the threesix months ended September 30,December 31, 2010:
                                
 Weighted    Weighted  
 Average    Average  
 Weighted Remaining Aggregate  Weighted Remaining Aggregate
 Average Contractual Intrinsic  Average Contractual Intrinsic
 Options Exercise Term Value  Options Exercise Term Value
 Outstanding Price (Years) (in millions)  Outstanding Price (Years) (in millions)
Options outstanding as of June 30, 2010 1,474,627 $57.05  1,474,627  $57.05 
Granted 215,412 76.30  232,412 77.34 
Exercised  (32,968) 44.21   (200,065) 48.72 
Canceled  (13,151) 68.77   (17,576) 69.65 
            
Options outstanding as of September 30, 2010 1,643,920 $59.74 6.56 $43.9 
Options outstanding as of December 31, 2010 1,489,398  $61.19 6.64 $84.6 
          
Options vested and expected to vest as of September 30, 2010 1,601,557 $59.44 6.48 $43.2 
Options vested and expected to vest as of December 31, 2010 1,454,476  $60.91 6.57 $83.0 
          
Exercisable as of September 30, 2010 965,177 $52.71 4.92 $32.6 
Exercisable as of December 31, 2010 882,740  $54.57 5.18 $56.0 
          

12


The total intrinsic value of options exercised duringin the first quarter of 2011six months ended December 31, 2010 was $1.5$9.7 million. As of September 30,December 31, 2010, there was $12.2were $11.2 million of total unrecognized compensation costcosts related to stock options. These costs are expected to be recognized over a weighted average period of 2.92.76 years.
The following assumptions were used to determine the fair value of the stock options using the Black-Scholes-Merton options pricing model for the threesix months ended September 30:December 31:
                
 2010 2009 2010 2009
Volatility  33%  33%  33%  34%
Risk-free interest rate  1.55%  2.53% 1.27% to 1.55%  2.5%
Expected life (in years) 4.7 4.6  4.7 4.7 
Expected dividend $0.00 $0.00  $0.00 $0.00 

14


Employee Stock Purchase Plan
The following assumptions were used to determine the fair value of ESPP shares for the threesix months ended September 30:December 31:
         
  2010 2009
Volatility  30%  36%
Risk-free interest rate  0.20%  0.30%
Expected life (in years)  0.50   0.50 
Expected dividend $0.00  $0.00 
The condensed consolidated statement of operations included the following stock-based compensation expense related to options, RSUs, PSUs, and ESPP for the three and six months ended September 30:December 31:
                
 Three Months Ended Six Months Ended 
         December 31, December 31, 
(in thousands) 2010 2009  2010 2009 2010 2009 
Cost of sales $234 $158  $256 $221 $490 $379 
Selling, general and administrative expenses 1,409 1,041  1,541 1,124 2,950 2,165 
Research and development expenses 330 379  388 352 718 731 
Tax benefit  (668)  (506)
              
Total $1,305 $1,072 
Total stock-based compensation expenses 2,185 1,697 4,158 3,275 
Tax effect on stock-based compensation  (740)  (584)  (1,408)  (1,090)
              
Net effect on net income $1,445 $1,113 $2,750 $2,185 
         
Note 10: Stockholders’ equity
Common Stock Repurchases
During the three and six months ended September 30,December 31, 2010, Dionexwe repurchased 187,18315,477 and 202,660 shares of our common stock, respectively, on the open market for approximately $14.0$1.4 million and $15.3 million (at an average repurchase price of $74.54$90.27 and $75.74, respectively, per share), compared with 188,253155,565 and 343,818 shares repurchasedof our common stock, respectively, on the open market for approximately $11.2$10.9 million and $22.0 million (at an average repurchase price of $59.36 and $64.06, respectively, per share) duringin the three months ended September 30, 2009.same period of the prior fiscal year.
Comprehensive Income
Comprehensive income consists of two components, net income and other comprehensive income. Other comprehensive income refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Dionex’s other comprehensive income consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency, unrealized gains (loss) on net investment hedge and unrealized gains and losses on available-for-sale securities, and net deferred gains and losses on these items.
The components of comprehensive income attributable to Dionex Corporation were as follows for the three and six months ended September 30 (in thousands):December 31:
                        
 2010 2009  Three Months Ended Six Months Ended 
 December 31, December 31, 
(in thousands) 2010 2009 2010 2009 
Net income, as reported $11,322 $10,586  $18,858 $16,920 $30,180 $27,507 
Foreign currency translation adjustments, net of taxes 9,215 4,862  817  (2,095) 10,032 2,767 
Unrealized loss on net investment hedge  (821)  (901)
Unrealized gain (loss) on net investment hedge, net of taxes  (365) 359  (1,186)  (542)
Unrealized gain on securities available for sale, net of taxes  1  1  1 1 
              
Comprehensive income 19,716 14,548  $19,311 $15,184 $39,027 $29,733 
Comprehensive income (loss) attributable to the noncontrolling interests 361 250 
Comprehensive income attributable to noncontrolling interests 383 338 744 588 
              
Comprehensive income attributable to Dionex Corporation $19,355 $14,298  $18,928 $14,846 $38,283 $29,145 
              

1315


Note 11: Income Taxes
As part of the process of preparing the condensed consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax exposure and assessing changes in temporary differences resulting from differing treatment of items, such as depreciation, amortization and inventory reserves, for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the condensed consolidated balance sheets.
Accounting standards relating to income taxes require that we continually evaluate the necessity of establishing or changing a valuation allowance for deferred tax assets, depending on whether it is more likely than not that actual benefit of those assets will be realized in future periods. We have evaluated our deferred tax assets as of December 31, 2010 and concluded that it is more likely than not that the deferred tax assets will be benefitedrealized in the future; therefore, the establishment or modification of a valuation allowance is not required. In addition, we adopted the provisions of the FASB’s accounting guidancestandard related to the accounting for uncertainty in income taxes. ThisThe accounting standard requires financial statement reporting of the expected future tax consequences of uncertain tax return reporting positions on the presumption that all relevant tax authorities possess full knowledge of those tax reporting positions, as well as all of the pertinent facts and circumstances, but it prohibits any discounting of any of the related tax effects for the time value of money.
Our total amount of unrecognized tax benefits as of September 30,December 31, 2010 was $8.1$7.6 million, of which $1.9 million, if recognized, would affect our effective tax rate compared to $8.0 million on June 30, 2010, of which $1.9 million, if recognized, would have affected our effective tax rate. The liability for income taxes associated with uncertain tax positions is classified in deferred and other income taxes payable.
We record interest and penalties related to unrecognized tax benefits in income tax expense. At September 30,December 31, 2010, we had approximately $1.9 million accrued for estimated interest related to uncertain tax positions compared to approximately $1.7 million on June 30, 2010. During the threesix months ended September 30,December 31, 2010, we accrued a total of $175,000$301,000 in interest on these uncertain tax positions. At September 30,December 31, 2010, we had approximately $69,000$38,000 accrued for estimated penalties related to uncertain tax positions compared to approximately $69,000 on June 30, 2010. During the fiscal yearperiod ended June 30,December 31, 2010, we accrued no additional penalties on these uncertain tax positions.
Included in our balance of income tax liabilities, accrued interest, and accrued penalties at September 30, 2010 of $10.2 million, is $3.9 million related to tax positions for which it is reasonably possible that the statute of limitations will expire in various jurisdictions within the next twelve months.
We are subject to audit by the Internal Revenue Service and California Franchise Tax Board for the fiscal years 2006 through the fiscal year 2009. As we have operations in most other US states, other state tax authorities may assess deficiencies related to prior year activities; however, the years open to assessment vary with each state. We also file income tax returns for non-US jurisdictions; the most significant of which are Germany, Japan, the UK and Hong Kong. The years open to adjustment for Germany are for the fiscal years 2004 through 2009, fiscal years 2004 through 2009 for the UK and Hong Kong and fiscal years 2003 through 2009 for Japan.
A number of years may elapse before an uncertain tax position is audited and ultimately settled. It is difficult to predict the ultimate outcome or the timing of resolution for uncertain tax positions. It is reasonably possible that the amount of unrecognized tax benefits could significantly increase or decrease within the next twelve months. These changes could result from the settlement of ongoing litigation, the completion of ongoing examinations, the expiration of the statute of limitations, or other circumstances. At this time, an estimate of the range of the reasonably possible change cannot be made.
Note 12: Commitments and Contingencies
In July 2008, Dionex acquired a Swedish company using a combination of cash and post acquisitionpost-acquisition earn-out payment arrangements.

14


Under the purchase agreement, earn-out payments of 70% for fiscal 2009, 30% for fiscal 2010 and 30% for 2011 as a percentage of the acquired company’s net income are payable to the seller at the end of each fiscal year. Each earn-outNo payments were accrued during the six months ended December 31, 2010 as we do not believe payment is contingent upon results of operations in which no payments were made during the three months ended September 30, 2010.probable.
Certain facilities and equipment are leased under non-cancelable operating leases. Dionex generally pays taxes, insurance and maintenance costs on leased facilities and equipment. Rental expense for all operating leases was $1.6 million and $2.0$2.1 million in the three months ended September 30,December 31, 2010 and 2009, respectively and $3.2 million and $4.1 million in the six months ended December 31, 2010 and 2009, respectively.

16


Minimum rental commitments under these non-cancelable operating leases were as follows as of September 30,December 31, 2010:
        
(In thousands)  
Less than 1 Year $6,277  $5,442 
1-2 Years 2,992  2,906 
2-3 Years 1,601  1,612 
3-4 Years 845  738 
4-5 Years 306  264 
After 5 Years 1,381  1,378 
      
Total $13,402  $12,340 
      
Dionex enters into standard indemnification agreements with many of our customers and certain other business partners in the ordinary course of business. These agreements include provisions for indemnifying the customer against any claim brought by a third party to the extent any such claim alleges that our product infringes a patent, copyright or trademark, or violates any other proprietary rights of that third party. The maximum potential amount of future payments Dionex could be required to make under these indemnification agreements is not estimable, however, Dionex has not incurred any costs to defend lawsuits or settle claims related to these indemnification agreements. No material claims for such indemnifications were outstanding as of September 30,December 31, 2010. Dionex has not recorded any liabilities for these indemnification agreements as of September 30,December 31, 2010 or June 30, 2010.
Note 13: Business Segment Information
The accounting standard for segment reporting establishes standards for reporting information about operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports of public business enterprises. It also establishes standards for related disclosures about products and services, geographic areas and major customers. Our business activities, for which discrete financial information is available, are regularly reviewed and evaluated by the chief operating decision maker (our Chief Executive Officer). As a result of this evaluation, Dionex determined that it has two operating segments: Chemical Analysis Business Unit (“CABU”) and Life Sciences Business Unit (“LSBU”).
CABU sells ion chromatography and sample preparation products, chromatography data systems software, services and related consumables. LSBU sells High Performance Liquid Chromatography (“HPLC”) products, chromatography data systems software, services and related consumables. These two operating segments are aggregated into one reportable segment for financial statement purposes. Both operating segments have similar economic characteristics; product processes; products and services; types and classes of customers; methods of distribution and regulatory environments. Because of these similarities, the two segments have been aggregated into one reporting segment for financial statement purposes.
Net sales for our products and services were as follows for the three and six months ended September 30:December 31:
                
 Six Months Ended Three Months Ended 
         December 31, December 31, 
(in thousands) 2010 2009  2010 2009 2010 2009 
Products $86,452 $79,282  $193,658 $172,892 $105,045 $93,610 
Installation and Training Services 2,580 2,480  7,029 6,170 4,449 3,691 
Maintenance 13,842 8,902  26,298 20,766 14,617 11,863 
              
 $102,874 $90,664  $226,985 $199,828 $124,111 $109,164 
              
Long-lived assets consist principally of property and equipment. No individualsingle customer accounted forcontributed more than 10% of net sales during the three and six months ended September 30,December 31, 2010 and 2009.2009, and net sales from services was less than 10% of net sales during the same period.

1517


ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Statement Regarding Forward-Looking Statements
Except for historical information contained herein, the discussion below and in the footnotes to our financial statements contained in this Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, and are made under the safe harbor provisions thereof. Such statements are subject to certain risks, uncertainties and other factors that may cause actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements, or industry results, expressed or implied by such forward-looking statements. Such risks and uncertainties include, among other things: general economic conditions, foreign currency fluctuations, risks associated with international sales, credit risks, fluctuations in worldwide demand for analytical instrumentation, fluctuations in quarterly operating results, competition from other products, existing product obsolescence, new product development, including market receptiveness, the ability to manufacture products on an efficient and timely basis and at a reasonable cost and in sufficient volume, the ability to attract and retain talented employees and other risks as described in more detail below under the heading “Risk Factors.” Readers are cautioned not to place undue reliance on these forward-looking statements that reflect management’s analysis only as of the date hereof. We undertake no obligation to update these forward-looking statements.
Overview
Dionex Corporation designs, manufactures, markets and services analytical instrumentation and related accessories and chemicals. Our products are used to analyze chemical substances in the environment and in a broad range of industrial and scientific applications. Our systems are used in environmental analysis and by the pharmaceutical, life sciences, chemical/petrochemical, power generation, food and electronics industries in a variety of applications.
Our current portfolio of liquid chromatography (LC) systems is focused in two product areas: ion chromatography (IC) and high performance liquid chromatography (HPLC). In addition, we offer a mass spectrometer detector that can be coupled with either IC or HPLC systems. For sample preparation, we provide accelerated solvent extraction (ASE®) systems and AutoTrace® instruments.instruments and consumables. In addition, we also develop and manufacture columns, consumables, suppressors, detectors, automation, and software analysis systems for use in or with liquid chromatography systems. All these products can be used to analyze chemical substances in the environment and in a broad range of industrial and scientific applications.
DuringOn December 12, 2010, Dionex, Thermo Fisher Scientific, Inc., a Delaware corporation (“Thermo Fisher”), and Weston D Merger Co., a Delaware corporation and a wholly owned subsidiary of Thermo Fisher (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Merger Sub will, subject to the past quarter,satisfaction or waiver of the conditions set forth in the Merger Agreement, merge with and into Dionex experienced steady growthand Dionex will survive the merger and continue as a wholly owned subsidiary of Thermo Fisher (the “Merger”). Pursuant to the terms of the Merger Agreement and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each share of common stock of Dionex issued and outstanding immediately prior to the Effective Time will be converted into the right to receive $118.50 in certaincash, without interest.
The Merger Agreement includes customary representations, warranties and covenants of Dionex and Thermo Fisher. Dionex has agreed to operate its business and the business of its end-user markets, including the life sciences, chemical/petrochemical, food and beverage and electronics markets. Demand from our customerssubsidiaries in the environmentalordinary course of business consistent with past practices until the Effective Time. Dionex has also agreed not to solicit, initiate, knowingly encourage or knowingly facilitate alternative acquisition proposals and electronics markets was relatively flat, while demandwill not knowingly permit its representatives to solicit or encourage any alternative acquisition proposal, in each case, subject to certain exceptions set forth in the Merger Agreement. The Merger Agreement contains certain termination rights, including, subject to the terms of the agreement, if the Dionex Board of Directors determines to accept a “Superior Proposal” as defined in the Merger Agreement, and also provides that under certain circumstances, upon termination, Dionex may be required to pay Thermo Fisher a termination fee of $65 million. The closing of the merger is currently expected to take place early in our power market was lower for the quarter. We experienced first quarter organic sales growth in all three of our major geographic regions. North America continued its strong sales performance from thefiscal fourth quarter of fiscal 2010 growing 22% compared with the first quarter of last year due to strong performance in our life science, chemical/petrochemical and food and beverage markets. In Europe, sales were up 9% in local currencies, but were negatively affected by currency fluctuation which resulted in 1% growth in reported dollars compared with last year. In Asia Pacific, sales in the first quarter of fiscal 2011 grew 21% in reported dollars and 17% in local currency driven by continued strong sales growth in India, Korea and Japan.pending regulatory approvals.

1618


Results of Operationsoperations:
The following table summarizes our consolidated statements of income for the first quarter of 2011three and six months ended December 31, 2010 as compared to the three and six months ended December 31, 2009, as a percentage of net sales for the periods indicated:
                                                
 Q1 2011 Q1 2010 Three months ended December 31 Six months ended December 31 
 % of    2010 2009 2010 2009 
 Net % of Net  % of % of % of % of 
(in thousands) Dollars Sales Dollars Sales 
    
(In thousands) Dollars Net sales Dollars Net sales Dollars Net sales Dollars Net sales 
Net sales $102,874  100.0% $90,664  100.0% $124,111  100.0% $109,164  100.0% $226,985  100.0% $199,828  100.0%
Cost of sales 36,472  35.5% 31,041  34.2% 43,322  34.9% 36,975  33.9% 79,794  35.2% 68,015  34.0%
                          
Gross profit 66,402  64.5% 59,623  65.8% 80,789  65.1% 72,189  66.1% 147,191  64.8% 131,813  66.0%
Operating expenses: 
Selling, general and administrative 40,266  39.2% 35,983  39.7% 43,920  35.5% 40,503  37.1% 84,186  37.1% 76,487  38.3%
Research and product development 8,013  7.8% 7,172  7.9% 9,370  7.5% 7,654  7.0% 17,383  7.7% 14,825  7.4%
                          
Total operating expenses 48,279  47.0% 43,155  47.6% 53,290  43.0% 48,157  44.1% 101,569  44.8% 91,312  45.7%
                          
Operating income 18,123  17.6% 16,468  18.2% 27,499  22.1% 24,032  22.0% 45,622  20.0% 40,501  20.3%
Interest income, net 27  0.0% 47  0.0%
Other income (expense), net  (1,038)  (1.0)% 40  0.1%
Interest income (expense), net 23  0.0% (4)  0.0% 50  0.0% 43  0.0%
 
Other expense, net  (516)  (0.4)%  (494)  (0.5)%  (1,554)  (0.6)%  (454)  (0.2)%
                          
Income before taxes 17,112  16.6% 16,555  18.3% 27,006  21.7% 23,534  21.5% 44,118  19.4% 40,090  20.1%
Taxes on income 5,790  5.6% 5,969  6.6% 8,148  6.5% 6,614  6.0% 13,938  6.1% 12,583  6.3%
                          
Net income 11,322  11.0% 10,586  11.7% 18,858  15.2% 16,920  15.5% 30,180  13.3% 27,507  13.8%
 
Less: Net income attributable to noncontrolling interests 361  0.4% 250  0.3% 383  0.3% 338  0.3% 744  0.3% 588  0.3%
                          
Net income attributable to Dionex $10,961  10.6% $10,336  11.4% $18,475  14.9% $16,582  15.2% $29,436  13.0% $26,919  13.5%
                          
Net sales
ConsolidatedFor the three and six months ended December 31, 2010, consolidated net sales increased 13%by $14.9 million or 14% and $27.1 million or 14%, respectively, as compared to the same corresponding period in the first quarter of fiscal 2011 compared to same period in prior year (excluding the net impact of unfavorable currency movements, net sales increased 15%).year. Our portfolio of HPLC systems was the largest contributorstrongly contributed to our consolidated net sales growth in part as a resultresults of our acquisition of the ESA Life Sciences Tools business (“ESA products”) inat the end of our first halfquarter of fiscal 2010, combined with the introduction of our UHPLC+ systems in fiscal 2010.2010 and greater market acceptance of our ICS-5000 RFIC systems. Dionex is subject to the effects of currency fluctuations, which have an impact on net sales. Currency fluctuations decreaseddid not have a significant impact on net sales for the three months ended December 31, 2010 and reduced sales by 2% in1 percentage point for the first quarter of fiscal 2011 compared to prior-year period.six months ended December 31, 2010.
Net sales increased acrossin all major regions primarilypartially as a result of a recovering global economy combined with continued strengthand greater market acceptance of our new IC and HLPC products. We continue to record strong results in China, India, and other emerging markets. Net salesNorth America. Sales outside of North America accounted for 70%74% of net revenue for the three months ended December 31, 2010 and 2009 and 72% and 73% of net sales infor the first quarter of 2011six months ended December 31, 2010 and 2010,2009, respectively. Sales directly to our end-user customers accounted for 95% and 93% for the three months ended and 95% and 94% for the six months ended in those same periods.fiscal 2010 and 2009, respectively. International distributors and representatives in Europe, Asia, and other international markets accounted for the remaining percentage of net sales.

19


Net sales from a regional perspective
North America- Net sales in this region increased 22%by 14% and 18% in reported dollars for the first quarter of fiscal 2011three and six months ended December 31, 2010, respectively, as compared to the same periodcorresponding periods in the prior fiscal year primarily due to the demand for our products in the power and life science food and beverage and power markets. The overall demand in this region was driven by our HPLC instruments, the ESA products, and in part, by our new ICS-5000 Capillary RFIC Systems (“ICS-5000”), introduced in the second half of fiscal 2010.
Europe- Net sales in this region increased 1%by 7% and 4% in reported dollars for the three and six months ended December 31, 2010, respectively, as compared to corresponding periods in the first quarter ofprior fiscal 2011 compared to same period in prior-yearyear (excluding the net impact of unfavorable currency movements, net sales increased 9%). The overall growth was primarily due to strong demandby 11% and 10%, respectively, in the chemicals and food and beverage markets, offset by softness in the life science and environmental markets. From a product perspective, growthsame periods). Growth in this region was driven by our HPLC portfolio, specifically ESA products added during fiscal 2010, and the introduction of the new UHPLC+ systems. In addition, we saw higher sales from our ICS-5000 products and IC consumables.
Asia / Pacific- Net sales in this region increased by 22% and 21% in reported dollars for the three and six months ended December 31, 2010, respectively, as compared to corresponding periods in the first quarter ofprior fiscal 2011 compared to the same period in prior year (excluding the net impact of favorable currency movements, net sales increased 17%)by 18% in those same periods). The overall growth was primarily due to continued strength in the countriescountry of China, Japan, India Korea and JapanKorea as well as overall strength in the life sciencespower, electronics, and chemical markets in this particular region.

17


chemicals markets. Our continued effort to make investments in our sales and service organization was pivotal to the growth in this region, combined with the revenuenet sales contributed from the ESA products.products in our HPLC portfolio.
Net sales from a product line perspective
IC - Net sales of our IC portfolio of products increased by 11% and 8% for the three and six months ended December 31, 2010, respectively, as compared to corresponding periods in the first quarter of 2011 compared to the same period in prior fiscal year primarily due to growth in North America and Asia/Pacific regions driven by the recovery of the global economy and higher demand in the life sciencepower, electronics, chemicals, and food and beverage markets for our IC systems, consumables and related services.
HPLC - Net sales of our HPLC portfolio of products increased 31% inby 21% and 25% for the first quarter of 2011three and six months ended December 31, 2010, respectively, as compared to the same periodcorresponding periods in the prior fiscal year primarilyin part due to the net sales generated from our ESA products acquired in the first half of fiscal 2010. Excluding net sales from our ESA products during the first quarter of fiscal 2011 andsix months ended December 31, 2010, net sales increased 14%by 16% over the same comparable period as a result of the rebounding global economystronger demand for our other HPLC products. In particular, growth resulted from the past few quarters, and in part, due to the introductionstrong acceptance of our newly introduced UHPLC+ systems in fiscal 2010.2010 and continued growth in certain emerging markets, such as China and India.
Gross Profit
Gross Profitprofit as a percentage of net sales for the three and six months ended December 31, 2010 was 65.1% and 64.8%, respectively, as compared to 66.1% and 66.0%, respectively, in the first quartercorresponding periods in the prior fiscal year. The decline in gross margin of fiscal 20111 and 1.2 percentage points for the three and six months ended December 31, 2010, respective, were 64.5% and 65.8%, respectively. The 1.3 percentage point declinerespectively, was drivenimpacted by increased sales of our ESA products acquired in fiscal 2010 which currently haveand a lower gross margin than our corporate average, as well as overall regionalcombination of product and geographical sales mix.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses as a percentage of net sales for the three and six months ended December 31, 2010 were approximately 39%35.5% and 40%37.1%, respectively, as compared to 37.1% and 38.3%, respectively, in the first quarter ofcorresponding periods in the prior fiscal 2011 and 2010, respectively.year. SG&A expenses increased $4.3by $3.4 million, or 12%8% and $7.7 million or 10% for the three and six months ended December 31, 2010, respectively, as compared to corresponding periods in the prior fiscal year primarily due to headcount increases, including staff added from the ESA acquisition, annual salary increase and increased travelling, selling and other expenses for the continued expansion efforts to increase our presence in Europe and Asia/Pacific regions.regions which attributed to the higher net sales reported. SG&A as a percentage of net sales declined compared to prior years due to better utilization of our sales and service organization.
Research and Product Development
Research and product development (R&D) expenses as a percentage of net sales for the three and six months ended December 31, 2010 were approximately 8%7.5% and 7.7%, respectively, as compared to 7.0% and 7.4%, respectively, in the first quarter ofcorresponding periods in the prior fiscal 2011 and 2010. While

20


year. R&D expenses increased $841,000,by $1.7 million or 11.7%22.4% and $2.6 million or 17.3% for the three and six months ended December 31, 2010, respectively, as compared to corresponding periods in the prior fiscal year, primarily due to the headcount increases from the ESA acquisition,increase in annual salary and higher R&D expenses. R&D expenses as a percentage of net sales was in line between both periods.
Interest Income
Interest income for the three and six months ended December 31, 2010 was $61,000 and $121,000, respectively, as compared to $32,000 and $115,000, respectively, in the first quarter ofcorresponding periods in the prior fiscal 2011 and 2010 was $60,000 and $83,000, respectively.year. Our interest income was affected by a combination of the maturity of one of our short-term investments and lower interest rates in the U.S. and Europe induring the first quarter of fiscal 2011.three and six months ended December 31, 2010.
Interest Expense
Interest expense for the three and six months ended December 31, 2010 was $38,000 and $71,000, respectively, as compared to $36,000 and $72,000, respectively, in the first quarter ofcorresponding periods in the prior fiscal 2011 and 2010 was $33,000 and $36,000, respectively.year. Our interest expense was affected theby combination of a higherlower average balance in our borrowing under the line of credit offset by lower interest rates in the first quarter of fiscal 2011.three and six months ended December 31, 2010.
Other Income (Expense),Expense, Net
Other income (expense),expense, net for the three and six months ended December 31, 2010 was $516,000 and $1,554,000, respectively, as compared to $494,000 and $454,000, respectively, in the first quarter ofcorresponding periods in the prior fiscal 2011 and 2010 was ($1.0 million), and $40,000, respectively.year. The changes were primarily due to losses on foreign currency transactions induring the first quarter of fiscal 2011.three and six months ended December 31, 2010.
Taxes on Income
Our tax rate may change over time as the amount and mix of income and taxes outside the U.S. changes. The effective tax rate is calculated using our projected annual pre-tax income and is affected by tax credits, the expected level of other tax benefits, and the impact of changes to the valuation allowance, as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

18


The taxes on income for the three and six months ended December 31, 2010 were $8.1 million and $13.9 million, respectively, as compared to $6.6 million and $12.6 million, respectively, in the first quarter ofcorresponding periods in prior fiscal 2011 and 2010 was $5.8 million and $5.9 million, respectively, representing anyear. The effective tax rate of 33.8%for three and 36.6%six months ended December 31, 2010 was 30.2% and 31.6%, respectively.respectively, as compared to 28.1% and 31.4%, respectively, in the corresponding periods in the prior fiscal year. The decreaseincrease in oureffective tax rate for the three months ended December 31, 2010 was primarily due to lower accrued interest on exposures. We anticipate that ourthe benefit of a favorable tax audit in the corresponding period in prior fiscal year. The change in the effective tax rate for fiscal 2011 will be in the range of 33% to 34%.six months ended December 31, 2010 and 2009 was not significant.
Net Income Attributable to Noncontrolling Interests
Net income attributable to noncontrolling interests for the three and six months ended December 31, 2010 was $0.4 million and $0.7 million, respectively, as compared to $0.3 million and $0.6 million, respectively, in the first quarter ofcorresponding periods in the prior fiscal 2011 and 2010 was $361,000 and $250,000, respectively.year. Net income attributable to noncontrolling interests represents the minority shareholders’ proportionate share of the net income recorded by three majority-owned international subsidiaries. The increase was due to better performance in India and Brazil.
Net Income Attributable to Dionex Corporation
Net income for the three and six months ended December 31, 2010 was $18.4 million and $29.4 million, respectively, as compared to $16.6 million and $26.9 million, respectively, in the first quarter ofcorresponding periods in the prior fiscal 2011 and 2010 was $11.0 million and $10.3 million, respectively, whileyear. The diluted earnings per share for three and six months ended December 31, 2010 were $0.62$1.04 and $0.57, respectively.$1.66, respectively, as compared to $0.92 and $1.49, respectively, in the corresponding periods in the prior fiscal year.
Liquidity and Capital Resources
As of September 30,December 31, 2010, we had cash and cash equivalents and short-term investments of $77.0$92.5 million. Our working capital as of December 31, 2010 was $143.7$176.4 million, an increase of $26.5$36.3 million from $117.2$140.1 million reported as of SeptemberJune 30, 2009.2010.

21


Cash generated by operating activities for first quarter in fiscal 2011the six months ended December 31, 2010 was $10.5$37.5 million, compared with $22.9$37.6 million for the same period last year. A higher level of income taxes payable due to lower payments made in fiscal 2011, a decrease in deferred revenues due to a lower level of prepaid income taxes, a decreaseuninstalled systems and service contracts sold at calendar year end, and an increase in accrued liabilities and accounts receivable due to lower salespayable contributed to a higher operating cash flows.flow. These changes were partially offset by a decrease to operating cash from an increase in inventory as we prepared foraccounts receivable due to higher shipments insales toward the end of the second quarter and a decrease in accounts payable and accrued liabilities due to higher payments made in the quarter.of fiscal 2010.
Cash used for investing activities was $9.4$11.8 million duringin the first quartersix months of fiscal 2011. Capital expenditures during the first quartersix months of 2011 were $5.2$7.8 million, which included purchases related to our general operations, purchase of land required for expansion of our manufacturing capacityfacility in Germering, Germany with the purchase of land, and effects of foreign currency translations. In addition, we also negotiated and completedpaid a paid-up royalty for $4.5 million related to our ESA products.
Cash providedused by financing activities was $3.2$5.2 million during the first quartersix months of fiscal 2011. Financing activities consisted primarily of common stock repurchases, partially offset by proceeds from issuances of shares pursuant to our equity incentive plans,plan, repayment of short-term obligations, and the tax benefits related to stock options in the first quartersix months of fiscal 2011.
Our available lines of credit totaled $11.8$28.9 million as of September 30,December 31, 2010. We believe our cash flow from operations, our existing cash and cash equivalents and our bank lines of credit will be adequate to meet our cash requirements for at least the next 12 months. The line of credit matures on December 31, 2011. The impact of inflation on our financial position and results of operations was not significant during any of the periods presented.

19


Contractual Obligations and Commercial Commitments
The following table summarizes our contractual obligations as of September 30,at December 31, 2010, and the payments due in future periods (in thousands):periods:
                                        
 Payments Due by Period  Payments Due by Period 
 Less        Less       
 Than 1 1-3 4-5 After 5 
(in thousands) Than 1 1-3 4-5 After 5 
Contractual Obligations Total Year Years Years Years  Total Year Years Years Years 
Short-Term Borrowings $17,371 $17,371 $ $ $  $52 $52 $ $ $ 
Long-Term Debt Associated with Business Purchase 527 527    
Debt Associated with Business Purchase 527 527    
Operating Lease Obligations 13,402 6,277 4,593 1,151 1,381  12,340 5,442 4,518 1,002 1,378 
                      
Total $31,300 $24,175 $4,593 $1,151 $1,381  $12,919 $6,021 $4,518 $1,002 $1,378 
                      
As of September 30,December 31, 2010, the liability for uncertain tax positions, net of offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and interest deductions was $1.9 million. As of September 30,December 31, 2010, the Company haswe had accrued $1.9 million of interest and $69,000$38,000 of penalties associated with its uncertain tax positions. The CompanyWe cannot conclude on the range of cash payments that will be made within the next twelve12 months associated with itsthese uncertain tax positions.
New Accounting Pronouncements
Refer to Note 1 in the Notes to Condensed Consolidated Financial Statements section.included elsewhere in the Quarterly Report in Form 10-Q..
Critical Accounting Policies and Estimates
The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. We evaluate our estimates, including those related to product returns and allowances, bad debts, inventory valuation, goodwill and other intangible assets, income taxes, warranty and installation provisions, and contingencies on an ongoing basis.
We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
There have been no significant changes during the three and six months ended September 30,December 31, 2010 to the items that we disclosed as our critical accounting policies and estimates in the Management’s Discussion and Analysis of Financial Condition and Results of

22


Operations section of our Annual Report on Form 10-K for the fiscal year ended June 30, 2010.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
We are exposed to financial market risks from fluctuations in foreign currency exchange rates, interest rates and stock prices of marketable securities. With the exception of the stock price volatility of our marketable equity securities, we manage our exposure to these and other risks through our regular operating and financing activities and, when appropriate, through our hedging activities. Our policy is not to use hedges or other derivative financial instruments for speculative purposes. We deal with a diversified group of major financial institutions to limit the risk of nonperformance by any one institution on any financial instrument. Separate from our financial hedging activities, material changes in foreign exchange rates, interest rates and, to a lesser extent, commodity prices could cause significant changes in the costs to manufacture and deliver our products and in customers’ buying practices. We have not substantially changed our risk management practices during fiscal 2010 or the first threesix months of fiscal 2011 and we do not currently anticipate significant changes in financial market risk exposures in the near future that would require us to change our current risk management practices.
Foreign Currency Exchange
Revenues generated from international operations are generally denominated in foreign currencies. We entered into forward foreign exchange contracts to hedge against fluctuations of intercompany account balances. Market value gains and losses on these hedge

20


contracts are substantially offset by fluctuations in the underlying balances being hedged, and the net financial impact is not expected to be material in future periods. As of September 30,December 31, 2010, we had forward exchange contracts to sell foreign currencies totaling approximately $32.7$21.9 million, including approximately $23.8$8.8 million in Euros, $6.7$6.4 million in Japanese yen, $1.0$1.2 million in Australian dollars, and $1.2 million in Canadian dollars.dollars, $3.7 million in British pound sterling, and $0.6 million in Swiss Francs. As of June 30, 2010, we had forward exchange contracts to sell foreign currencies totaling approximately $23.7 million, including approximately $17.7 million in Euros, $4.3 million in Japanese yen, $0.8 million in Australian dollars and $0.9 million in Canadian dollars. The foreign exchange contracts outstanding at the end of the period mature within one month. As of September 30,December 31, 2010 and June 30, 2010, we have approximately $1.5$0.4 million and $0.3 million, respectively, in other current liabilities in the condensed consolidated balance sheets related to the foreign currency exchange contracts. For the threesix months ended September 30,December 31, 2010 and 2009, we recorded realized pre-tax losses of approximately $2.2$3.0 million and $0.7$0.6 million, respectively, related to the closed foreign exchange forward contracts.
Dionex uses a $10 million cross-currency swap arrangement for Japanese yen that expires in March 2012 to hedge the exchange rate exposure of our net investment in our Japanese subsidiary. Dionex considers the impact of its counterparty’s credit risk on the fair value of the contract as well as the ability to each party to execute under the contract. Dionex assessed and documented hedge effectiveness of the contract and designated it as a net investment hedge at the inception date, January 1, 2008. We reassess hedge effectiveness on a quarterly basis. The effective portion of the gain or loss on the hedge is reported in accumulated other comprehensive income as part of the foreign currency translation adjustment.
Interest and Investment Income
Our interest and investment income is subject to changes in the general level of U.S. interest rates. Changes in U.S. interest rates affect the interest earned on our cash equivalents and short-term investments. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to our investment balances as of September 30,at December 31, 2010 and June 30, 2010 indicated that such market movement would not have a material effect on our business, operating results or financial condition. Actual gains or losses in the future may differ materially from this analysis, depending on our actual balances and changes in the timing and amount of interest rate movements.
Debt and Interest Expense
AsAt December 31, 2010, we had short-term borrowings of September 30, 2010, Dionex had an outstanding balance under a borrowing line of credit of $17.4 million.$52,000. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to our outstanding debt balance as of September 30,at December 31, 2010, indicated that such market movement would not have a material effect on our business, operating results or financial condition. Actual gains or losses in the future may differ materially from this analysis, depending on changes in the timing and amount of interest rate movements and the level of borrowings maintained by us.

23


ITEM 4. CONTROLS AND PROCEDURES
We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our “disclosure controls and procedures” (as defined in rules promulgated under the Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30,December 31, 2010 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and Chief Financial Officer have concluded that these controls and procedures are effective at the “reasonable assurance” level. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a Company have been detected.
ThereDuring the quarter ended December 31, 2010, there were no changes into our overall internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Securities Exchange Act) during the period covered by this quarterly report on Form 10-Q that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.10-Q.

21


PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Litigation Related to the Tender Offer
On December 14, 2010, Dr. Alan Weisberg filed a putative class action lawsuit in the Superior Court of the State of California, County of Santa Clara, purportedly on behalf of the stockholders of Dionex, against Dionex, its directors and Thermo Fisher, alleging, among other things, that Dionex’s directors, aided and abetted by Dionex and Thermo Fisher, breached their fiduciary duties owed to Dionex stockholders in connection with the proposed acquisition of Dionex by Thermo Fisher and Purchaser. The complaint seeks, among other things, to enjoin the defendants from completing the acquisition as currently contemplated. Dionex intends to take all appropriate actions to defend the lawsuit.
ITEM 1A. RISK FACTORS
You should consider carefully the following risk factors as well as other information in this report before investing in any of our securities. If any of the following risks actually occur, our business operating results and financial condition could be adversely affected. This could cause the market price for our common stock to decline, and you may lose all or part of your investment. These risk factors include any material changes to, and supersede, the risk factors previously disclosed in our most recent annual report on Form 10-K.10-K and our quarterly report for the first quarter of fiscal 2011.
Failure to complete the acquisition by Thermo Fisher Scientific, Inc. (“Thermo Fisher”) could negatively impact our stock price and adversely affect our future financial condition, operations and prospects.
If our acquisition by Thermo Fisher is not completed for any reason, we may be subject to a number of material risks, including the following:
if the merger agreement is terminated, we may be required in specific circumstances, to pay a termination fee of $65 million to Thermo Fisher;
the price of our common stock may decline to the extent that the current market price of our stock reflects an assumption that the acquisition will be completed;
we must pay significant transaction-related expenses related to the acquisition, including substantial legal and accounting fees, and other expenses related to the acquisition, even if the acquisition is not completed.
These risks could negatively impact our stock price and adversely affect our future financial condition, operations and prospects. If the merger agreement is terminated and our Board of Directors determines to seek another merger or business combination, it may not be able to find a party willing to pay an equivalent or more attractive price than that which would have been paid in the Tender Offer or Merger with Thermo Fisher.

24


Our operations may be disrupted by the transaction with Thermo Fisher.
Our day to day operations may be disrupted due to the substantial time and effort our management must devote to complete the transaction. In addition, our current and prospective employees may experience uncertainty about their future role with us or Thermo Fisher. This may adversely affect our ability to attract and retain key management and other personnel.
A downturn in economic conditions could affect our operating results.
Our business, financial condition and results of operations have been affected by the weaker global economic conditions of the last several years. These conditions resulted in reduced sales of our products in the last two quarters of fiscal 2009 and the first two quarters of fiscal 2010. In a continued economic recession or under other adverse economic conditions, our customers may be less likely to purchase our products and vendors may be more likely to fail to meet contractual terms. A further downturn in economic conditions or a slow recovery from the current recession may make it more difficult for us to maintain and continue our revenue growth and profitability performance resulting in a material adverse effect on our business.
Foreign currency fluctuations related to international operations may adversely affect our operating results.
We derived over 70% of our net sales from outside the U.S. in fiscal 2010 and expect to continue to derive the majority of net sales from outside the U.S. for the foreseeable future. Most of our sales outside the U.S. are denominated in the local currency of our customers. As a result, the U.S. dollar value of our net sales varies with currency rate fluctuations. Significant changes in the value of the U.S. dollar relative to certain foreign currencies could have a material adverse effect on our results of operations. In recent periods, our results of operations have been positively affected from the depreciation of the U.S. dollar against the Euro, the Japanese yen and several other foreign currencies, but there can be no assurance that this positive impact will continue. In the past, our results of operations have also been negatively impacted by the appreciation of the U.S. dollar against other currencies.
Economic, political and other risks associated with international sales and operations could adversely affect our results of operations.
Because we sell our products worldwide and have significant operations outside of the U.S., our business is subject to risks associated with doing business internationally. We anticipate that revenue from international operations will continue to represent a majority of our total net sales. In addition, we expect that the proportion of our employees, contract manufacturers, suppliers, job functions and manufacturing facilities located outside the U.S. will increase. Accordingly, our future results could be harmed by a variety of factors, including:
  interruption to transportation flows for delivery of parts to us and finished goods to our customers;
 
  changes in a specific country’s or region’s economic, political or other conditions;
 
  trade protection measures and import or export licensing requirements;
 
  difficulty in staffing and managing widespread operations;
 
  differing labor regulations;
 
  differing protection of intellectual property;
 
  unexpected changes in regulatory requirements; and
 
  geopolitical turmoil, including terrorism and war.
If we fail to effectively transition to our new and/or upgraded accounting information and technology infrastructure systems, it may have an adverse impact on our business and results of operations.

2225


We may experience difficulties in transitioning to new or upgraded accounting information and technology infrastructure systems, including loss of data and decreases in productivity as personnel become familiar with new, upgraded or modified systems. Our accounting information and technology infrastructure systems will require modification and refinement as we grow and as our business and customers’ needs change, which could prolong the difficulties we experience with systems transitions, and we may not always employ the most effective information systems. If we experience difficulties in implementing new or upgraded accounting information and technology infrastructure systems or experience significant system failures, or if we are unable to successfully modify our accounting information and technology infrastructure systems and respond to changes in our customers’ needs in a timely manner, it may have an adverse impact on our business and results of operations.
We continually evaluate our system of internal controls over financial reporting and may make enhancements where appropriate, which may require significant resources.
Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. We continually evaluate and, where appropriate, enhance our policies, procedures and internal controls. If we fail to maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we could be subject to regulatory scrutiny and investors could lose confidence in the accuracy and completeness of our financial reports. In addition, failure to maintain adequate internal controls could result in financial statements that do not accurately reflect our financial condition. Implementing changes when necessary may take a significant amount of time, money, and management resources and may require specific compliance training of our directors, officers and other personnel.
Changes in our provision for income taxes or adverse outcomes resulting from examination of our income tax returns could adversely affect our results.
Our provision for income taxes is subject to volatility and could be adversely affected by earnings being lower than anticipated in countries that have lower tax rates and higher than anticipated in countries that have higher tax rates; by changes in the valuation of our deferred tax assets and liabilities; by expiration of or lapses in the R&D tax credit laws; by transfer pricing adjustments; by tax effects of nondeductible compensation; by changes in accounting principles; or by changes in tax laws and regulations including possible U.S. or foreign changes to the taxation of earnings of our foreign subsidiaries, and the deductibility of expenses attributable to foreign income, or the foreign tax credit rules. Significant judgment is required to determine the recognition and measurement attribute prescribed in Financial Accounting Standards Board (FASB) Accounting Standards Codification 740,Income Taxes(“ASC 740”) (formerly referenced as FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes —an interpretation of FASB Statement No. 109”). ASC 740 applies to all income tax positions, including the potential recovery of previously paid taxes, which if settled unfavorably could adversely impact our provision for income taxes or additional paid-in capital. In addition, we are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other tax authorities. We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There can be no assurance that the outcomes from these continuous examinations will not have an adverse effect on our operating results and financial condition.
Natural disasters, terrorist attacks or acts of war may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our net sales, costs and expenses, and financial condition.
We have significant manufacturing and distribution facilities, particularly in the western U.S. (i.e. California)California and in Germany. In particular, California has experienced a number of earthquakes, wildfires, flooding, landslides and other natural disasters in recent years. Occurrences of these types of events could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. Terrorist attacks have contributed to economic instability in the U.S. (such as those that occurred on September 11, 2001), and further acts of terrorism, bioterrorism, violence or war could affect the markets in which we operate, our business operations, our expectations and other forward-looking statements contained or incorporated in this document. Any of these events could have an adverse effect on our operating results and financial condition.
We may experience difficulties with obtaining components from sole- or limited-source suppliers, or manufacturing delays, either of which could adversely affect our results of operations.
Most raw materials, components and supplies that we purchase are available from many suppliers. However, certain items are purchased from sole or limited-source suppliers and a disruption of these sources could adversely affect our ability to ship products as needed. A prolonged inability to obtain certain materials or components would likely reduce product inventory, hinder sales and harm our reputation with customers. Worldwide demand for certain components may cause the cost of such components to rise or limit the availability of these components, which could have an adverse effect on our results of operations.
We manufacture products in our facilities in Germany, the Netherlands and the U.S. Any prolonged disruption to the operations at these facilities, whether due to labor unrest, supplier issues, damage to the physical plants or equipment or other reasons, could also adversely affect our results of operations.
If we fail to properly transition manufacturing currently performed at the ESA Biosciences facility to our manufacturing facilities in Germany and Sunnyvale, we may experience shipment delays, cost overruns, excess inventory and other problems, which may adversely impact our business and operating results.
In fiscal year 2011, we currently plan to transitionWe are in the process of transitioning manufacturing of our Corona, electrochemical detectors and flow cells from the ESA Biosciences manufacturing facility in Massachusetts to our manufacturing facilities in Germany and Sunnyvale. This transition is

26


scheduled to be completed by the end of fiscal 2011. If the transition does not go as expected, it could potentially result in the following in addition to other potential issues, each of which couldmay have an adverse effect on our business and operating results and our business reputation:
•  delay of shipments;
•  unexpected cost overruns; and
•  
delay of shipments;
unexpected cost overruns; and
overstock of inventory as a result of building excessive buffer stock.
Credit risks associated with our customers may adversely affect our financial position or result of operations.

23


Because trade credit is extended to many of our customers, the current global economic condition may adversely affect our ability to collect on accounts receivable that are owed to us. In general, our customers are evaluated for their credit worthiness as part of our operating policy, and letters of credit are utilized to mitigate credit risks when possible. We believe we have adopted the appropriate operating policies to address the customer credit risk under a stable economic environment. Nevertheless, given the current global economic situation we could experience delays in collection on accounts receivable that are owed to us. As a result, this could adversely affect our financial position or result of operations.
Fluctuations in worldwide demand for analytical instrumentation could affect our operating results.
The demand for analytical instrumentation products can fluctuate depending upon capital expenditure cycles. Most companies consider our instrumentation products capital equipment and some customers may be unable to secure the necessary capital expenditure approvals due to general economic or customer specific conditions. Significant fluctuations in demand could harm our results of operations.
We may experience difficulties with obtaining components from sole- or limited-source suppliers, or manufacturing delays, either of which could adversely affect our results of operations.
Most raw materials, components and supplies that we purchase are available from many suppliers. However, certain items are purchased from sole or limited-source suppliers and a disruption of these sources could adversely affect our ability to ship products as needed. A prolonged inability to obtain certain materials or components would likely reduce product inventory, hinder sales and harm our reputation with customers. Worldwide demand for certain components may cause the cost of such components to rise or limit the availability of these components, which could have an adverse effect on our results of operations.
We manufacture products in our facilities in Germany, the Netherlands and the U.S. Any prolonged disruption to the operations at these facilities, whether due to labor unrest, supplier issues, damage to the physical plants or equipment or other reasons, could also adversely affect our results of operations.
Fluctuations in our quarterly operating results may cause our stock price to decline.
A high proportion of our costs are fixed due in part to our significant sales and marketing, research and product development and manufacturing costs. Declines in revenue caused by fluctuations in currency rates, worldwide demand for analytical instrumentation or other factors could disproportionately affect our quarterly operating results, which may in turn cause our stock price to decline.
A significant portion of our cash is maintained overseas.
Most of our short-term debt is in the U.S. While there is a substantial cash requirement in the U.S. to fund operations and capital expenditures, service debt obligations, finance potential acquisitions and continue authorized stock repurchases, a significant portion of our cash is maintained and generated from foreign operations. Our financial condition and results of operations could be adversely impacted if we are unable to maintain a sufficient level of cash flow in the U.S. to address these requirements through cash from U.S. operations, efficient and timely repatriation of cash from overseas and other sources obtained at an acceptable cost.
Our results of operations and financial condition will suffer if we do not introduce new products that are attractive to our customers on a timely basis.
Our products are highly technical in nature. As a result, many of our products must be developed months or even years in advance of the potential need by a customer. If we fail to introduce new products and enhancements as demand arises or in advance of the

27


competition, our products are likely to become obsolete over time, which would harm operating results. Also, if the market is not receptive to our newly-developed products, our results of operations would be adversely impacted and we may be unable to recover the costs of research and product development and marketing associated with such products.
The analytical instrumentation market is highly competitive, and our inability to compete effectively in this market would adversely affect our results of operations and financial condition.
The analytical instrumentation market is highly competitive and we compete with many companies on a local and international level that are significantly larger than we are and have greater resources, including larger sales forces and technical staff. Competitors may introduce more effective and less costly products and, in doing so, may make it difficult for us to acquire and retain customers. If this occurs, our market share may decline and operating results could suffer.

24


Our executive officers and other key employees are critical to our business, they may not remain with us in the future and finding talented replacements may be difficult.
Our operations require managerial and technical expertise. Each of our executive officers and key employees is employed “at will” and may leave our employment at any time. In addition, we operate in a variety of locations around the world where the demand for qualified personnel may be extremely high and is likely to remain so for the foreseeable future. As a result, competition for personnel can be intense and the turnover rate for qualified personnel may be high. The loss of any of our executive officers or key employees could cause us to incur increased operating expenses and divert senior management resources in searching for replacements. An inability to hire, train and retain sufficient numbers of qualified employees would seriously affect our ability to conduct our business.
We may be unable to protect our intellectual property rights and may face intellectual property infringement claims.
Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of third parties. We cannot be certain that:
  any of our pending patent applications or any future patent applications will result in issued patents;
 
  the scope of our patent protection will exclude competitors or provide competitive advantages to us;
 
  any of our patents will be held valid if subsequently challenged; or
 
  others will not claim rights in or ownership of the patents and other proprietary rights held by us.
Furthermore, we cannot be certain that others have not or will not develop similar products, duplicate any of our products or design around any patents issued, or that may be issued, in the future to us or to our licensors. Whether or not patents are issued to us or to our licensors, others may hold or receive patents which contain claims having a scope that covers products developed by us. We could incur substantial costs in defending any patent infringement suits, whether or not such suits have merit, or in asserting any patent rights, including those granted by third parties. In addition, we may be required to obtain licenses to patents or proprietary rights from third parties. There can be no assurance that such licenses will be available on acceptance terms, if at all.
Our issued U.S. patents, and corresponding foreign patents, expire at various dates ranging from 2010 to 2029. When each of our patents expires, competitors may develop and sell products based on the same or similar technologies as those covered by the expired patent. We have invested in significant new patent applications, and we cannot be certain that any of these applications will result in an issued patent to enhance our intellectual property rights.

28


ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Repurchases
During the three months ended September 30, 2010, weWe repurchased shares of our common stock under a systematic program to manage the dilution created by shares issued under employee stock plans and for other purposes. This program authorizes repurchases in the open market or in private transactions. We started a series of repurchase programs in fiscal 1989 with the Boardboard of Directors most recentlydirectors authorizing in October 2008 future repurchases of 1,000,000an additional 1.0 million shares of common stock in October 2009 as well as authorizing the repurchase of additional shares of common stock equal to the number of shares of common sharesstock issued pursuant to our employee stock plans.

25


The following table indicates common shares repurchased and additional shares added to the repurchase program during the three months ended September 30,December 31, 2010:
ISSUER PURCHASES OF EQUITY SECURITIES
                     
          Total      
          Number of     Maximum
          Shares     Number of
          Purchased Additional Shares that
  Total Avg. as Part of Shares May Yet Be
  Number Price Publicly Authorized Purchased
  of Shares Paid Announced for Under the
Period Purchased per Share Program Purchase (1) Program (2)
July 1 to July 31, 2010        8,589,669      817,844 
August 1 to August 31, 2010  106,207  $73.49   8,695,876   18,894   730,531 
September 1 to September 30, 2010  80,976  $75.92   8,776,852   32,905   682,460 
                     
Total  187,183  $74.54   8,776,852   51,799   682,460 
                     
          Total      
          Number of     Maximum
          Shares     Number of
          Purchased Additional Shares that
  Total Avg. as Part of Shares May Yet Be
  Number Price Publicly Authorized Purchased
  of Shares Paid Announced for Under the
Period Purchased per Share Program Purchase (1) Program (2)
October 1 - 31, 2010        8,776,852   49,495   731,955 
November 1 - 30, 2010  15,477  $90.27   8,792,329   76,816   793,294 
December 1 - 31, 2010        8,792,329   40,786   834,080 
                     
Total  15,477  $90.27   8,792,329   167,097   834,080 
 
(1) The number of shares represents the number of shares issued pursuant to employee stock plans that are authorized for purchase.
 
(2) The number of shares includes (i) 1.0 million shares of common stock approved for repurchases in October 2008,2009, plus (ii) that number of shares of common stock equal to the number of shares issued pursuant to employee stock plans subsequent to October 20082009 minus the number of shares repurchased, plus (iii) the number of shares remaining from the repurchase authorization in August 2006.
Dividends
As of September 30,December 31, 2010, we had paid no cash dividends on our common stock and we do not anticipate doing so in the foreseeable future.

2629


EXHIBIT INDEX
Item 6. EXHIBITS
EXHIBIT INDEX
           
Exhibit        
Number Description Reference Description Reference
3.1 Restated Certificate of Incorporation, filed December 12, 1988  (1) Restated Certificate of Incorporation, filed December 12, 1988  (1)
            
3.2 Certificate of Amendment of Restated Certificate of Incorporation, filed December 1, 1999 (Exhibit 3.2)  (8) Certificate of Amendment of Restated Certificate of Incorporation, filed December 1, 1999 (Exhibit 3.2)  (8)
            
3.3 Amended and Restated Bylaws, August 6, 2008 (Exhibit 99.1)  (12) Amended and Restated Bylaws, August 6, 2008 (Exhibit 99.1)  (12)
            
10.1* Medical Care Reimbursement Plan as amended October 30, 2007 (Exhibit 10.1)  (9) Medical Care Reimbursement Plan as amended October 30, 2007 (Exhibit 10.1)  (9)
            
10.2 Credit Agreement dated December 23, 2009 between Wells Fargo Bank and Dionex Corporation (Exhibit 10.2)  (4) Credit Agreement dated December 23, 2009 between Wells Fargo Bank and Dionex Corporation (Exhibit 10.2)  (4)
            
10.3* Management Incentive Bonus Plan dated August 6, 2009 (Exhibit 99.1)  (6) Management Incentive Bonus Plan dated August 6, 2009 (Exhibit 99.1)  (6)
            
10.4* Dionex Corporation 2004 Equity Incentive Plan, as amended October 2007 (Exhibit 10.1)  (10) Dionex Corporation 2004 Equity Incentive Plan, as amended October 2007 (Exhibit 10.1)  (10)
            
10.5* Form of Stock Option Agreement for non-employee directors (Exhibit 10.5)  (11) Form of Stock Option Agreement for non-employee directors (Exhibit 10.5)  (11)
            
10.6* Form of Stock Option Agreement for other than non-employee directors (Exhibit 10.6)  (11) Form of Stock Option Agreement for other than non-employee directors (Exhibit 10.6)  (11)
            
10.7* Form of Stock Unit Award Agreement (Exhibit 10.2)  (10) Form of Stock Unit Award Agreement (Exhibit 10.2)  (10)
            
10.8* Form of International Stock Option Agreement (Exhibit 10.8)  (9) Form of International Stock Option Agreement (Exhibit 10.8)  (9)
            
10.9* Form of Stock Unit Award Agreement for U.S. employees  (2) Form of Stock Unit Award Agreement for U.S. employees  (2)
            
10.10* Form of Stock Unit Award Agreement for International employees  (2) Form of Stock Unit Award Agreement for International employees  (2)
            
10.11* Employee Stock Participation Plan (Exhibit 10.13)  (5) Employee Stock Participation Plan (Exhibit 10.13)  (5)
            
10.12* Form of Performance Stock Unit Grant Notice  (3) Form of Performance Stock Unit Grant Notice  (3)
            
10.13* Change in Control Severance Benefit Plan as amended April 26, 2010  (2) Change in Control Severance Benefit Plan as amended December 12, 2010 (Exhibit 10.1)  (14)
            
10.14* Summary of Compensation Arrangements with named executive officers  (7) Summary of Compensation Arrangements with named executive officers  (7)
            
10.15* Form of Indemnification Agreement (Exhibit 10.1)  (13) Form of Indemnification Agreement (Exhibit 10.1)  (13)
            
10.16* Agreement and Plan of Merger with Thermo Fisher Scientific, Inc. dated December 12, 2010 (Exhibit 2.1)  (14)
      
10.17* First Amendment to Employee Stock Purchase Plan (Exhibit 10.1)  (14)
      
10.18* Letter dated December 15, 2010 between Dionex Corporation and Frank Witney  (14)
      
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002     Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002    
            
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002     Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002    
            
32.1† Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    
            
32.2† Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    
101.INS XBRL Instance Document    
101.SCH XBRL Taxonomy Extension Schema Document    
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document    
101.LAB XBRL Taxonomy Extension Label Linkbase Document    
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document    
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB XBRL Taxonomy Extension Label Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
 
(1) Incorporated by reference to the indicated exhibit in our Form 10-Q filed September 20, 1989.
 
(2) Incorporated by reference to the indicated exhibit in our Form 8-K10-K filed April 28, 2010.August 29, 2008.
 
(3) Incorporated by reference to the indicated exhibit in our Form 10-K filed August 27, 2010.
 
(4) Incorporated by reference to the indicated exhibit in our Form 10-Q filed February 9, 2010.
 
(5) Incorporated by reference to the indicated exhibit in our Form 10-K filed September 10, 2004.
 
(6) Incorporated by reference to the indicated exhibit in our Form 8-K filed August 10, 2009.
 
(7) Incorporated by reference to the indicated exhibit in our Form 8-K filed August 9, 2010 and August 16, 2010.
 
(8) Incorporated by reference to the indicated exhibit in our Form 10-K filed August 29, 2007.
 
(9) Incorporated by reference to the indicated exhibit in our Form 10-Q filed November 9, 2007.
 
(10) Incorporated by reference to the indicated exhibit in our Form 8-K filed October 15, 2007.
 
(11) Incorporated by reference to the indicated exhibit in our Form 10-Q filed February 8, 2008.
 
(12) Incorporated by reference to the indicated exhibit in our Form 8-K filed August 11, 2008.
 
(13) Incorporated by reference to the indicated exhibit in our Form 8-K filed November 3, 2008.
 
(14)Incorporated by reference to the indicated exhibit in our Form 8-K filed December 16, 2010.
* Management contract or compensatory plan or arrangement.
 
 This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

2730


SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.
DIONEX CORPORATION
(Registrant)
Date: November 8, 2010     
 DIONEX CORPORATION
(Registrant)
 
By:
Date: February 8, 2011 By:  /s/ Craig A. McCollam
Craig A. McCollam
  
  Craig A. McCollam 
  Executive Vice President and Chief Financial Officer

(Signing as Principal Financial and Accounting

Officer, and as Authorized Signatory of
Registrant)  
 Registrant)

2831


EXHIBIT INDEX
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
32.1 Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
32.2 Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document

2932